Edition:
India

Argos Therapeutics Inc (ARGS.OQ)

ARGS.OQ on NASDAQ Stock Exchange Capital Market

0.29USD
20 Apr 2018
Change (% chg)

$-0.04 (-12.90%)
Prev Close
$0.33
Open
$0.34
Day's High
$0.36
Day's Low
$0.27
Volume
849,926
Avg. Vol
147,911
52-wk High
$11.95
52-wk Low
$0.27

Latest Key Developments (Source: Significant Developments)

Argos Therapeutics Reports Results Of Interim Analysis Of The Adapt Trial And Announces Review Of Strategic Alternatives
Thursday, 19 Apr 2018 

April 19 (Reuters) - Argos Therapeutics Inc ::ARGOS THERAPEUTICS REPORTS RESULTS OF INTERIM ANALYSIS OF THE ADAPT TRIAL AND ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES.ARGOS THERAPEUTICS INC - COMPANY TO TERMINATE ADAPT STUDY.ARGOS THERAPEUTICS INC - COMPANY HAS RETAINED STIFEL TO PROVIDE ADVICE ON POSSIBLE STRATEGIC ALTERNATIVES.ARGOS THERAPEUTICS INC - TRADING IN COMMON STOCK TO BE TRANSFERRED FROM NASDAQ TO OTCQB VENTURE MARKET.ARGOS THERAPEUTICS - STRATEGIC ALTERNATIVES MAY INCLUDE A POTENTIAL MERGER OR SALE OF CO.ARGOS - ESTIMATED MEDIAN OVERALL SURVIVAL FOR COMBO ARM WAS 28.2 MONTHS VERSUS 31.2 MONTHS FOR CONTROL ARM IN MOST RECENT ANALYSIS OF ADAPT TRIAL DATA.ARGOS - TWO OTHER CO-PRIMARY ENDPOINTS IN ADAPT TRIAL ALSO DID NOT DEMONSTRATE A FAVORABLE RESULT.ARGOS - FOURTH ENDPOINT, FIVE-YEAR SURVIVAL, WAS NOT EVALUATED IN ADAPT TRIAL AS THERE WAS INSUFFICIENT DATA.  Full Article

Argos Therapeutics Board Approves One-For-Twenty Reverse Split Of Co's Common Stock Effective Jan 18, After Close
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Argos Therapeutics Inc ::ARGOS ANNOUNCES ONE-FOR-TWENTY REVERSE STOCK SPLIT.ARGOS THERAPEUTICS - BOARD APPROVED ONE-FOR-TWENTY REVERSE SPLIT OF CO'S COMMON STOCK THAT WILL TAKE EFFECT JANUARY 18, AFTER CLOSE OF TRADING.  Full Article

Argos Therapeutics Enters Into Agreement With Saint-Gobain Performance Plastics Corp
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Argos Therapeutics Inc ::ARGOS THERAPEUTICS - ‍ON NOV 22, ENTERED INTO A SATISFACTION AND RELEASE AGREEMENT WITH SAINT-GOBAIN PERFORMANCE PLASTICS CORP - SEC FILING.ARGOS THERAPEUTICS-UNDER AGREEMENT,CO AGREED TO MAKE, ISSUE & DELIVER TO SAINT-GOBAIN, AN UNSECURED CONVERTIBLE PROMISSORY NOTE IN AMOUNT OF $2.4 MLN‍​.ARGOS - ‍IN CONNECTION WITH DEAL, CO, SAINT-GOBAIN ENTERED INTO AMENDMENT TO DEVELOPMENT DEAL TO EXTEND TERM OF DEVELOPMENT DEAL TO DEC 31, 2019​.ARGOS THERAPEUTICS- UNDER AGREEMENT,CO AGREED TO MAKE, ISSUE & DELIVER TO SAINT-GOBAIN,CASH PAYMENT OF $500,000, 689,995 SHARES OF CO'S COMMON STOCK.  Full Article

Argos Provides Financial Update
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Argos Therapeutics Inc ::ARGOS PROVIDES FINANCIAL UPDATE.ARGOS THERAPEUTICS - ‍TKC PROPERTIES HAS, WITH ARGOS' FULL CONSENT, SUCCESSFULLY COMPLETED SALE OF FACILITY IN DURHAM COUNTY, NC TO A THIRD PARTY​.ARGOS THERAPEUTICS-RAISED ABOUT $6.8 MILLION NET PROCEEDS UNDER ITS AT-THE-MARKET STOCK ISSUANCE FACILITY WITH COWEN & CO SUBSEQUENT TO Q3 CLOSE ON SEPT 30​.ARGOS THERAPEUTICS - ‍IN CONNECTION WITH DEAL, CO ENTERED LEASE TERMINATION DEAL WITH TKC, TO WHICH CO RECEIVED CASH PROCEEDS OF ABOUT $1.8 MILLION​.ARGOS THERAPEUTICS INC - ‍COMPANY BELIEVES IT NOW HAS SUFFICIENT CASH TO EXECUTE ITS BUSINESS PLAN AT LEAST THROUGH JUNE 2018​.  Full Article

Argos reports third quarter financial results
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Argos Therapeutics Inc :Argos reports third quarter 2017 financial results and operational highlights.Qtrly loss per share $0.10 ‍​.  Full Article

Argos Therapeutics files for offering of 13.5 mln shares of common stock by Invetech
Saturday, 4 Nov 2017 

Nov 3 (Reuters) - Argos Therapeutics Inc :Argos Therapeutics files for offering of 13.5 million shares of common stock by Invetech Pty Ltd - SEC filing.  Full Article

BRIEF-Pharmstandard International reports open market purchase of 53,524 shares of Argos Therapeutics at avg price of $4.23/shr
Wednesday, 24 Aug 2016 

Corrects headline to say Pharmstandard International purchased shares of Argos Therapeutics.Argos Therapeutics Inc : Pharmstandard International SA reports open market purchase of 53,524 shares of co's common stock at average price of $4.23 per share on Aug. 19 .Pharmstandard International SA reports purchase of 21,950 shares of co's common stock at average price of $4.26 per share on Aug. 22.  Full Article

Argos Therapeutics Q2 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S
Thursday, 11 Aug 2016 

Argos Therapeutics Inc : Argos Therapeutics reports second quarter 2016 financial results and recent operational highlights . Q2 revenue $500,000 versus $100,000 . Q2 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.48 .Q2 revenue view $196,000 -- Thomson Reuters I/B/E/S.  Full Article

Argos Therapeutics announces proposed public offering of common stock and warrants
Thursday, 28 Jul 2016 

Argos Therapeutics Inc :Argos Therapeutics announces proposed public offering of common stock and warrants.  Full Article

Argos Therapeutics files for common stock offering
Saturday, 23 Jul 2016 

Argos Therapeutics Inc :Files for common stock offering of up to 19.5 mln shares by the selling shareholders - SEC filing.  Full Article

BRIEF-Argos Therapeutics Reports Q4 Loss Per Share $0.38

* ARGOS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS